¿Semax y Selank funcionan sin SSRI o deben ser combinados?

Pueden funcionan monoterapia intrinsicamente. Semax + Selank + GHRP-6 target multiple depression mechanisms (BDNF, GABA, neuroinflammación, neuroprotección) que SSRIs address indirectamente. Muchos responders alcanza remisión péptidos sola sin SSRI. Recomendación: mild-moderate depression—probé péptidos 4-8 minggu monoterapia, assess response. Si respuesta suboptimal, agregu SSRI. Severa depression inicial—considere SSRI + péptidos combinación para faster onset, redundancia mecánica.

¿Cuáles son diferencias Semax vs. Selank en depresión manejo?

SEMAX primarily mood/cognition (BDNF, anhedonia, motivation). SELANK primarily anxiety/stress (GABA, NPY). Depresión frecuentemente anxiety + low mood comorbid, entonces ambos complementarios. Semax si primarily anhedonia/flat affect. Selank si anxiety dominante. Idealmente ambos (Semax + Selank) maximum efficacy basado emerging evidence. Timing: Selank puede faster anxiolytic onset (days), Semax mood improvement variable (1-2 minggu intrinsic + 4-8 minggu BDNF cumulative).

¿Qué pasa si discontinúo SSRI para comenzar protocol peptido?

ABRUPT discontinuation SSRI = discontinuation syndrome (anxiety, insomnia, flu-like symptoms). Approach gradual: taper SSRI over 4-8 minggu MIENTRAS initiate peptido protocol. Week 1-2: full SSRI dose + iniciar Semax, Selank, GHRP-6 (permite peptido stabilization). Week 3-6: SSRI reduce 50% (taper gradual), péptidos full dose. Week 7-10: SSRI 25% (o discontinue), peptido monotherapy assess. Si withdrawal symptoms problematic, slower taper (8-12 minggu). Objetivo: péptido replacement estable antes SSRI complete discontinuation.

Salud Mental y Depresión: Optimización Nootrópica con Péptidos

Categorías: Mejora Cognitiva, Salud Mental, Nootrópicos

Depresión causada BDNF (brain-derived neurotrophic factor) deficiency, neuroinflammación, HPA axis dysregulation (estrés crónico). Péptidos restauran BDNF signaling, reduce neuroinflammación, optimizan serotonina/dopamina, restituyen neuroplasticidad.

Resumen Simplificado

Semax 500-700mcg intranasal 1-2x/día (BDNF amplification, neuroprotección). Selank 100-300mcg intranasal 1-2x/día (anxiolytic, anti-depressant, GABA modulation). GHRP-6 100-200mcg 2x/día (GH → IGF-1 → BDNF neuroprotección). Magnesio 400-600mg nightly (NMDA receptor modulation, mood stabilization). Timeline: mood improvement 1-2 minggu, neuroinflammación reduction 4-8 minggu, completa remisión depressión 8-16 minggu.

Semax: BDNF Amplification dan Neuroprotección

SEMAX (Met-Glu-His-Phe-Pro-Gly-Pro): heptapeptida derived ACTH (adrenocorticotropic hormone), synthetic peptide. MEKANISME SEMAX: (1) BDNF expression increase brain (hippocampus, cortex, amygdala); (2) neurotrophic factor signaling cascade (TrkB receptor activation); (3) neuroinflammation reduction (TNF-α, IL-6 suppression). BDNF ROLE DEPRESION: 'neurotrophin hypothesis' depression—BDNF low implicated depression pathophysiology. Antidepressants (SSRIs, SNRIs) trabaj primarily increasing serotonin, secondarily increase BDNF (delayed onset, weeks lag). SEMAX direct BDNF amplification via non-serotonergic mechanism (trabaj independent neurotransmitter availability). DOSIS SEMAX: 500-700mcg intranasal (spray or liquid drops) 1-2x/día (morning + midday optimal). INTRANASAL ABSORPTION: bypassa blood-brain barrier, direct brain access (olfactory epithelium transneuronal pathway). EFFICACY: plasma BDNF levels increase 30-50% within 2-4 minggu. Mood symptoms improvement: anhedonia reduction, motivation increase, emotional blunting resolution 1-2 minggu intrinsic BDNF effect. NEUROPLASTICITY RECOVERY: depression characterized impaired neuroplasticidad (reduced neurogenesis, hippocampal atrophy). SEMAX restore neurogenesis (BDNF → neural progenitor cell proliferation), neuroprotection atrophy reversal 4-8 minggu. COMBINATION SSRIs: SEMAX synergize SSRIs—additive BDNF elevation, faster antidepressant onset (~2 minggu vs. 4-6 minggu SSRI monotherapy).

Selank: Anxiolytic, GABAergic Modulation, Stress Resilience

SELANK (Thr-Lys-Pro-Arg-Pro-Gly-Pro): heptapeptida derived tuftsin, enkephalin analog. ANXIOLYTIC MECHANISM: (1) GABAergic tone enhancement (GABA-A receptor modulation); (2) monoamine rebalancing (serotonin, dopamina potentiation); (3) neuropeptide Y (NPY) upregulation—stress resilience peptide. DOSIS SELANK: 100-300mcg intranasal 1-2x/día (same intranasal delivery Semax, compatible coadministration). EFFICACY ANXIETY: faster anxiolytic onset vs. SSRI (1-2 minggu vs. 4-6 minggu). GABAergic effect benzodiazepine-like (reduced anxiety) without dependence/tolerance risk (peptido mechanism preserved endogeny). NPY STRESS RESILIENCE: NPY elevated chronically stressed humans linked fear/PTSD resistance. Selank upregulate NPY → improve stress buffering, emotional regulation. DEPRESSION SECONDARY BENEFIT: anxiety-depression comorbidité common; Selank address anxiety component directly (complementary Semax BDNF restoration). PROTOCOL COMBINATION: Semax (BDNF, cognitive) + Selank (GABA, anxiety) = comprehensive depresión management. TIMELINE COMBINED: week 1 anxiety reduction (Selank GABA-A), week 1-2 mood/anhedonia improvement (Semax BDNF), week 4-8 complete neuroinflammación resolution (sustained effect).

GHRP-6: Neuroprotection via GH-IGF-1-BDNF Axis

GHRP-6 (GH Releasing Peptide-6): secretagogue direct GH amplification. GH BRAIN FUNCTION: crosses BBB-receptor, stimulat IGF-1 local brain production (astrocytes, neurons). IGF-1 NEUROPROTECTION: (1) BDNF potentiation (IGF-1 → mTOR → BDNF gene expression); (2) neuroinflammation suppression (microglia cytokine reduction); (3) neurogenesis promotion (hippocampal neural progenitor proliferation). DEPRESSION GH ROLE: GH deficiency-like state depression (low IGF-1). GH restoration reverse neuroinflammation, restore neurogenesis. DOSIS GHRP-6: 100-200mcg subcutaneous 2x/día (morning + evening GH secretion windows). CJC-1295 SYNERGY: 500-1000mcg IM weekly (potentiate GHRP-6 GH output). EFEKTIVITAS DEPRESSION: combined GHRP-6 + Semax + Selank = multitarget BDNF restoration (Semax direct, GHRP-6 indirect via IGF-1). IGF-1 increase 20-40% within 3-4 minggu. TIMELINE GHRP-6 DEPRESSION: secondary benefit to Semax (faster Semax effect 1-2 minggu), cumulative benefit GHRP-6 4-8 minggu. Particularly effective if baseline GH low (measured IGF-1 <80 ng/mL).

Integrative Protocol and Lifestyle Factors

COMPREHENSIVE DEPRESSION MANAGEMENT: pharmacologic (Semax, Selank, GHRP-6) + nutritional (magnesium, omega-3, vitamin D, B vitamins) + lifestyle (exercise, sleep, social connection). MAGNESIUM 400-600mg NIGHTLY: NMDA receptor antagonism (similar ketamine mechanism—antidepressant potential), mood stabilization, sleep improvement. Deficiency common depression. L-THEANINE 100-200mg (pairs Selank anxiolytic, enhance GABA). OMEGA-3 (EPA 2g + DHA 1g daily): membrane fluidity brain, anti-inflammatory, neurogenesis support. VITAMIN D 2000-4000 IU: mood regulation, neuroinflammation reduction (especially if deficiency). B VITAMINS (B6, B12, folate): neurotransmitter synthesis, methylation support, neuroinflammation reduction. EXERCISE 30-60 minuto moderate 3-4x/minggu: BDNF amplification (equivalent pharmacologic), neurogenesis, mood improvement. SLEEP OPTIMIZATION: 7-9 horas nightly, consistent timing—glymphatic system clearance (neuroinflammatory metabolites removal during sleep). SOCIAL CONNECTION: isolation depression risk factor; peptido protocol + social engagement maximize outcomes. PROTOCOL DOSING SUMMARY: Semax 500-700mcg intranasal 1-2x/día + Selank 100-300mcg intranasal 1-2x/día + GHRP-6 100mcg 2x/día + magnesium 400-600mg nightly + omega-3 + exercise + sleep optimization. TIMELINE DEPRESSION REMISSION: 1-2 minggu initial mood improvement (Selank anxiolytic + Semax BDNF). 2-4 minggu significant anhedonia/motivation recovery (BDNF effect consolidation). 4-8 minggu neuroinflammation full resolution, neuroplasticity recovery evident (cognition sharpness), remisión induction 60-70% depressed patients. SSRI TAPER: if currently SSRI, considere slow taper over 4-8 minggu while peptido protocol established (avoid discontinuation syndrome).

Hallazgos Clave

Semax 500-700mcg intranasal 1-2x/día: BDNF amplification 30-50%, mood improvement 1-2 minggu, neuroprotection restoration
Selank 100-300mcg intranasal 1-2x/día: GABAergic anxiolytic, NPY stress resilience, anxiety reduction without dependence
GHRP-6 100-200mcg 2x/día: IGF-1 neuroprotection, BDNF potentiation indirect, cumulative depression benefit 4-8 minggu
Magnesium + omega-3 + exercise: synergistic BDNF amplification, neuroinflammation reduction, lifestyle integration
Protocolo integral: Semax + Selank + GHRP-6 + lifestyle = depression remission 60-70% within 8-16 minggu

Productos relacionados

Semax
Selank

Más artículos en Mejora Cognitiva

Más artículos en Salud Mental

Términos del glosario

bdnf

Preguntas frecuentes

¿Semax y Selank funcionan sin SSRI o deben ser combinados?: Pueden funcionan monoterapia intrinsicamente. Semax + Selank + GHRP-6 target multiple depression mechanisms (BDNF, GABA, neuroinflammación, neuroprotección) que SSRIs address indirectamente. Muchos responders alcanza remisión péptidos sola sin SSRI. Recomendación: mild-moderate depression—probé péptidos 4-8 minggu monoterapia, assess response. Si respuesta suboptimal, agregu SSRI. Severa depression inicial—considere SSRI + péptidos combinación para faster onset, redundancia mecánica.
¿Cuáles son diferencias Semax vs. Selank en depresión manejo?: SEMAX primarily mood/cognition (BDNF, anhedonia, motivation). SELANK primarily anxiety/stress (GABA, NPY). Depresión frecuentemente anxiety + low mood comorbid, entonces ambos complementarios. Semax si primarily anhedonia/flat affect. Selank si anxiety dominante. Idealmente ambos (Semax + Selank) maximum efficacy basado emerging evidence. Timing: Selank puede faster anxiolytic onset (days), Semax mood improvement variable (1-2 minggu intrinsic + 4-8 minggu BDNF cumulative).
¿Qué pasa si discontinúo SSRI para comenzar protocol peptido?: ABRUPT discontinuation SSRI = discontinuation syndrome (anxiety, insomnia, flu-like symptoms). Approach gradual: taper SSRI over 4-8 minggu MIENTRAS initiate peptido protocol. Week 1-2: full SSRI dose + iniciar Semax, Selank, GHRP-6 (permite peptido stabilization). Week 3-6: SSRI reduce 50% (taper gradual), péptidos full dose. Week 7-10: SSRI 25% (o discontinue), peptido monotherapy assess. Si withdrawal symptoms problematic, slower taper (8-12 minggu). Objetivo: péptido replacement estable antes SSRI complete discontinuation.

Volver a la biblioteca de investigación